ABBV vs PFE
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | ABBV | PFE | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $264.96 | $28.07 | |
| Market cap as of 2026-08-24 | $468.2B | $160.0B | |
| P/E as of 2026-08-24 | 70.24 | 35.19 | PFE lower |
| PEG as of 2026-08-24 | 6.59 | -2.72 | PFE lower |
| Net margin as of 2026-08-24 | +9.8% | +6.8% | ABBV higher |
| Gross margin as of 2026-08-24 | +72.8% | +74.7% | PFE higher |
| Operating margin as of 2026-08-24 | +26.2% | +6.8% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | +4.9% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | +2.1% | ABBV higher |
| Debt / equity as of 2026-08-24 | 49.22 | 0.74 | PFE lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | -0.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -14.8% | ABBV higher |
| Dividend yield as of 2026-08-24 | +4.5% | +5.4% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.22 | 0.28 | |
| 1-year return as of 2026-08-21 close | +26.5% | +9.1% | ABBV higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.